GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?
Robert P Young1,2, Raewyn J Hopkins1, Bryan A Hay1, Gregory D Gamble11Schools of Biological Science and Health Sciences, University of Auckland, 2Department of Medicine, Auckland City Hospital, Auckland, New ZealandBackground: Studies over the past two decades have reported associations between GSTM...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-09-01
|
Series: | The Application of Clinical Genetics |
Online Access: | http://www.dovepress.com/gstm1-null-genotype-in-copd-and-lung-cancer-evidence-of-a-modifier-or--a8275 |
id |
doaj-6ab110d096754497a2a1df034a8ad5f6 |
---|---|
record_format |
Article |
spelling |
doaj-6ab110d096754497a2a1df034a8ad5f62020-11-24T23:47:24ZengDove Medical PressThe Application of Clinical Genetics1178-704X2011-09-012011default137144GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?Young RPHopkins RJHay BAGamble GDRobert P Young1,2, Raewyn J Hopkins1, Bryan A Hay1, Gregory D Gamble11Schools of Biological Science and Health Sciences, University of Auckland, 2Department of Medicine, Auckland City Hospital, Auckland, New ZealandBackground: Studies over the past two decades have reported associations between GSTM1 (glutathione S-transferase mu 1) null genotype and chronic obstructive pulmonary disease (COPD) or lung cancer. However, a modifier or confounding effect from COPD mediating the GSTM1 association with lung cancer has not been previously explored.Aim and methods: This variant was examined in a case-control study of current or former smokers with COPD (n = 669), lung cancer (n = 454), or normal lung function (n = 488). Sex, age, and smoking history were comparable between groups.Results: The GSTM1 null genotype was found to be more frequent in smokers with COPD alone (odds ratio [OR] 1.30, 95% confidence interval [CI] 1.02–1.66, P = 0.031) and lung cancer (OR 1.26, 95% CI 0.96–1.65, P = 0.083) than in matched smokers with normal lung function (62%, 61%, and 56%, respectively). However, when smokers with lung cancer were subgrouped according to the presence of COPD, then the association with all COPD subjects (OR 1.34, 95% CI 1.07–1.70, P = 0.010) and with COPD and lung cancer (OR 1.50, 95% CI 1.06–2.12, P = 0.018) continued to be significant while that with lung cancer only was reduced (OR 1.11, 95% CI 0.78–1.56, P = 0.55). These associations were independent of age, sex, height, lung function, and smoking history.Conclusion: Findings suggest that COPD is an important subphenotype of lung cancer and may underlie previously reported associations with the GSTM1 null genotype.Keywords: lung cancer, chronic obstructive pulmonary disease, GSTM1, association study, polymorphism, copy number varianthttp://www.dovepress.com/gstm1-null-genotype-in-copd-and-lung-cancer-evidence-of-a-modifier-or--a8275 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Young RP Hopkins RJ Hay BA Gamble GD |
spellingShingle |
Young RP Hopkins RJ Hay BA Gamble GD GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect? The Application of Clinical Genetics |
author_facet |
Young RP Hopkins RJ Hay BA Gamble GD |
author_sort |
Young RP |
title |
GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect? |
title_short |
GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect? |
title_full |
GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect? |
title_fullStr |
GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect? |
title_full_unstemmed |
GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect? |
title_sort |
gstm1 null genotype in copd and lung cancer: evidence of a modifier or confounding effect? |
publisher |
Dove Medical Press |
series |
The Application of Clinical Genetics |
issn |
1178-704X |
publishDate |
2011-09-01 |
description |
Robert P Young1,2, Raewyn J Hopkins1, Bryan A Hay1, Gregory D Gamble11Schools of Biological Science and Health Sciences, University of Auckland, 2Department of Medicine, Auckland City Hospital, Auckland, New ZealandBackground: Studies over the past two decades have reported associations between GSTM1 (glutathione S-transferase mu 1) null genotype and chronic obstructive pulmonary disease (COPD) or lung cancer. However, a modifier or confounding effect from COPD mediating the GSTM1 association with lung cancer has not been previously explored.Aim and methods: This variant was examined in a case-control study of current or former smokers with COPD (n = 669), lung cancer (n = 454), or normal lung function (n = 488). Sex, age, and smoking history were comparable between groups.Results: The GSTM1 null genotype was found to be more frequent in smokers with COPD alone (odds ratio [OR] 1.30, 95% confidence interval [CI] 1.02–1.66, P = 0.031) and lung cancer (OR 1.26, 95% CI 0.96–1.65, P = 0.083) than in matched smokers with normal lung function (62%, 61%, and 56%, respectively). However, when smokers with lung cancer were subgrouped according to the presence of COPD, then the association with all COPD subjects (OR 1.34, 95% CI 1.07–1.70, P = 0.010) and with COPD and lung cancer (OR 1.50, 95% CI 1.06–2.12, P = 0.018) continued to be significant while that with lung cancer only was reduced (OR 1.11, 95% CI 0.78–1.56, P = 0.55). These associations were independent of age, sex, height, lung function, and smoking history.Conclusion: Findings suggest that COPD is an important subphenotype of lung cancer and may underlie previously reported associations with the GSTM1 null genotype.Keywords: lung cancer, chronic obstructive pulmonary disease, GSTM1, association study, polymorphism, copy number variant |
url |
http://www.dovepress.com/gstm1-null-genotype-in-copd-and-lung-cancer-evidence-of-a-modifier-or--a8275 |
work_keys_str_mv |
AT youngrp gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect AT hopkinsrj gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect AT hayba gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect AT gamblegd gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect |
_version_ |
1725489889764442112 |